The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Opdivo (nivolumab) Market Be By 2030 Compared To Its 2026 Market Size?
The opdivo (nivolumab) market size has experienced significant growth in recent years. It is anticipated to expand from $8.34 million in 2025 to $9.01 million in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. Historically, this expansion has been driven by the approval of PD-1 inhibitors, the increasing global cancer burden, the inherent limitations of chemotherapy, impressive clinical trial outcomes, and the growing adoption of immunotherapy by oncologists.
The market size for Opdivo (nivolumab) is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $12.13 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this projected growth include its application in new oncology indications, the proliferation of combination therapy protocols, enhanced patient selection through biomarkers, a rise in cancer diagnosis rates, and increased expenditure on oncology healthcare. Key trends expected during this period involve the broadening application of immune checkpoint inhibitors, a greater uptake of combination immunotherapy regimens, the expansion of PD-1 based cancer treatments, its increased utilization across numerous cancer indications, and an emphasis on achieving improved long-term survival outcomes.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp
Which Major Drivers Are Influencing The Expansion Of The Opdivo (nivolumab) Market?
The opdivo (nivolumab) market is projected to expand propelled by the rising prevalence of non-small cell lung cancer (NSCLC). This form of lung cancer accounts for roughly 85% of all lung cancer cases, with its growing incidence primarily stemming from factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo functions by inhibiting the PD-1 receptor on immune cells, thereby enhancing the body’s immune response to identify and attack cancer cells. For instance, in 2024, the American Cancer Society, a US-based health organization, reported 234,580 new cases of lung cancer diagnosed in the US, with 80% being NSCLC, indicating an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Consequently, the increasing incidence of non-small cell lung cancer is a key driver for the growth of the opdivo (nivolumab) market.
How Are Segments Identified Within The Opdivo (nivolumab) Market Segment Framework?
The opdivo (nivolumab) market covered in this report is segmented –
1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL
2) By Dosage: Injection, Solution, Other Dosages
3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
4) By End-User: Hospitals, Clinics, Other End Users
Which Trends Are Shaping The Opdivo (nivolumab) Market?
Major companies operating in the opdivo (nivolumab) market are primarily focused on creating advanced combination therapies designed to improve treatment efficacy, circumvent resistance mechanisms, and broaden their application across various cancer types. Combination therapy, in this context, signifies the deliberate use of Opdivo (nivolumab) alongside other agents, such as chemotherapy, to deliver a more comprehensive treatment strategy for individuals with advanced cancer. As an example, in October 2024, the Food and Drug Administration, a US-based federal agency, granted approval for Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for use as a neoadjuvant treatment, subsequently followed by single-agent nivolumab as adjuvant therapy after surgery, for adults diagnosed with resectable non-small cell lung cancer who do not possess known EGFR or ALK mutations. This approval facilitates the utilization of Opdivo both preceding and following surgical intervention, thereby enhancing therapeutic outcomes for suitable patients.
Who Are The Companies Competing Within The Opdivo (nivolumab) Market?
Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical
Get The Full Opdivo (nivolumab) Market Report:
https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-
Which Geographic Region Dominates The Opdivo (nivolumab) Market?
North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Opdivo (nivolumab) Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-
Browse Through More Reports Similar to the Global Opdivo (nivolumab) Market 2026, By The Business Research Company
Nivolumab Market Report 2026
https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report
Data Lake Market Report 2026
https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report
Market Research Services Market Report 2026
https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model